As per MRFR analysis, the US Artificial Heart Market Size was estimated at 1.05 (USD Billion) in 2023. The US Artificial Heart Market Industry is expected to grow from 1.25 (USD Billion) in 2024 to 6 (USD Billion) by 2035. The US Artificial Heart Market CAGR (growth rate) is expected to be around 15.327% during the forecast period (2025 - 2035).
The US Artificial Heart Market is witnessing significant trends driven by advancements in technology and increasing patient needs. One of the key market drivers is the rising prevalence of cardiovascular diseases, which is a leading cause of death in the United States. As the population ages and lifestyle-related ailments increase, more patients are looking for heart replacement options. Innovations in artificial heart technology, including improved design, biocompatibility, and miniaturization, are further driving market growth.
Opportunities are emerging in the development of next-generation devices that promise enhanced functionality and longevity, catering not only to patients awaiting heart transplants but also to those who may not qualify for traditional surgery. Recently, there has been a growing focus on the integration of artificial hearts with digital health technologies, enabling better patient monitoring and data collection. This digital shift allows for real-time health management and personalized treatment plans, making artificial heart therapy more effective and accessible.
Additionally, the rise of outpatient surgical procedures is transforming how patients receive artificial heart interventions, reducing hospital stays and costs involved with traditional methods. Various initiatives and support from healthcare organizations in the US aim to promote awareness of artificial heart options, which is fostering acceptance among both patients and healthcare professionals. Research into new materials and designs continues to expand, creating further opportunities for innovation in the US market. With the combination of advanced technology, a growing patient base, and supportive healthcare policies, the US Artificial Heart Market is poised for substantial growth in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Artificial Heart Market Industry is being significantly driven by the rising incidence of cardiovascular diseases among the population. According to the Centers for Disease Control and Prevention (CDC), about 697,000 individuals in the United States died from heart disease in 2020, accounting for 1 in every 5 deaths. This alarming statistic underscores a critical health issue that is fostering the growth of the artificial heart market. As the population ages and lifestyle diseases become more common, the demand for advanced heart failure treatments, including artificial hearts, is anticipated to escalate.
Furthermore, organizations such as the American Heart Association are actively promoting awareness and education on heart health, pushing advancements in innovative treatment options which in turn catalyzes market growth and innovation in the artificial heart sector.
Rapid technological advancements are a vital driver for the US Artificial Heart Market Industry. Innovations in materials and design, backed by extensive Research and Development (R&D) efforts from various medical device firms like Abbott Laboratories and Medtronic, are making artificial hearts more efficient and reliable. Newer iterations exhibit longer durability and better patient outcomes. For instance, the development of continuous-flow left ventricular assist devices (LVADs) has greatly improved heart function in patients awaiting transplants.
The Food and Drug Administration (FDA) has also been more proactive in approving devices, with a reported increase of 20% in expeditious device approvals during the past five years, enabling quicker market entry for groundbreaking technologies.
Increasing awareness and acceptance of advanced medical technologies among both healthcare providers and patients are propelling the US Artificial Heart Market Industry forward. According to a survey conducted by the American College of Cardiology, over 70% of patients with heart diseases express openness to using artificial heart technologies upon receiving adequate education concerning the risks and benefits. Moreover, public campaigns led by organizations such as the National Heart, Lung, and Blood Institute are working towards increasing understanding of heart failure management options, thereby fostering a more accepting atmosphere for artificial heart solutions.
This shift in mindset helps drive growth in adoption rates of artificial heart procedures as more patients seek advanced treatments.
The US Artificial Heart Market Industry is also being positively affected by favorable regulatory environments and evolving reimbursement policies. The Centers for Medicare & Medicaid Services (CMS) have recognized and updated reimbursement frameworks to provide better compensation for heart failure treatments, including artificial hearts. This adjustment has been evident in the increase in reimbursement rates for related procedures by approximately 15% over the last three years, thus encouraging healthcare providers to adopt and implement advanced technologies.
Additionally, with the introduction of newer procedural codes exploring the treatment of advanced heart failure, the artificial heart sector stands to gain significantly from a more business-friendly environment, leading to heightened innovation and adoption.
The US Artificial Heart Market is diverse and segmented primarily by Type, revealing a comprehensive landscape characterized by significant advancements in medical technology. Within this segment, the Heart-Lung Machine is crucial for providing cardiac and respiratory support during surgeries, illustrating its essential role in complex procedures, particularly in cardiothoracic operations. Mechanical Hearts serve as a pivotal alternative for patients experiencing severe heart failure, acting as a temporary solution while patients await transplants, thereby addressing the shortage of available donor organs.
Total Artificial Hearts represent a remarkable innovation that can replace the heart entirely, providing life-altering capabilities for patients with end-stage heart disease and illustrating advancements in device reliability and patient outcomes. Ventricular Assist Devices (VADs) have gained considerable traction as they assist heart function and blood flow in patients with weakened hearts, making them a vital component in heart failure management and supporting patients prior to and following heart transplantation. The growing prevalence of heart diseases in the US, coupled with advancements in surgical techniques and device technology, underscores the importance of each type within the market.
Furthermore, increasing investment in Research and Development activities within the healthcare sector is poised to drive innovations in the artificial heart space, further bolstering the capabilities and efficacy of these devices. The overall aging population, combined with rising cardiovascular disorders, enhances the urgency for robust solutions encapsulated within these segment types. The integration of cutting-edge technology and data-driven healthcare approaches aligns with the evolving needs of patients and healthcare providers, reflecting robust potential in market growth. As such, each segment thrives under increasing focus on improving patient care, outcomes, and quality of life, establishing the US Artificial Heart Market as a multi-faceted and essential part of the broader healthcare environment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The End User segment of the US Artificial Heart Market plays a vital role in accommodating the growing demand for artificial heart technologies, primarily through Hospitals and Clinics, as well as Specialty Centers. Hospitals and Clinics are significant hubs for cardiac care, providing essential procedures and follow-up services for patients with severe heart conditions. They typically have specialized personnel and technological capabilities to effectively manage complex heart procedures, which enhances patient outcomes and fosters technological advancements in artificial heart devices.
Specialty Centers focus on treating specific heart conditions with tailored interventions, leading to improved diagnostic and therapeutic efficiency. They often attract patients who are seeking advanced treatment options, reinforcing their importance in the overall healthcare ecosystem. The collaborative nature of these End Users supports research and development initiatives, driving continuous innovations in artificial hearts. Additionally, the increasing prevalence of heart diseases in the US further emphasizes the relevance of these facilities, as they are crucial for delivering state-of-the-art care to a growing patient population. Overall, the strategic positioning of Hospitals and Clinics alongside Specialty Centers in the US Artificial Heart Market enables them to effectively meet the dynamic healthcare demands of patients with cardiac ailments.
The US Artificial Heart Market is characterized by intense competition among key players who are striving to innovate and improve their product offerings. As the prevalence of heart diseases continues to escalate, the demand for artificial hearts to treat severe cases of heart failure is rising. Various companies are focusing on research and development to create devices that enhance patient outcomes and address the limitations of existing technologies. The market landscape is influenced by several factors, including regulatory approvals, technological advancements, partnerships, and collaborations that companies pursue to stay ahead in the competitive scenario. With an increasing aging population and growing awareness about cardiovascular diseases, companies are continuously looking to capture market share through differentiated product strategies and effective marketing initiatives.
Medtronic, a leading player in the US Artificial Heart Market, has established a significant presence due to its robust range of cardiovascular devices and solutions. The company is known for its innovative ventricular assist devices, which are crucial for patients who are not candidates for heart transplants or are awaiting transplantation. Medtronic's strengths lie in its comprehensive research and clinical programs aimed at validating the effectiveness of its products. The company’s commitment to advancing technology for cardiac support is evident in its continuous investment in R&D, helping to maintain a competitive edge. Additionally, Medtronic benefits from an extensive distribution network and collaborations with healthcare systems, which enable it to reach a wider patient base and enhance its market penetration across the United States.
Abbott Laboratories is another formidable entity in the US Artificial Heart Market, recognized for its advancements in heart implant technologies. The company offers a variety of products like left ventricular assist devices and has made notable advancements in heart failure management. With a strong portfolio, Abbott Laboratories strengthens its position through its commitment to innovation and a focus on patient-centric solutions. The company has engaged in strategic mergers and acquisitions to amplify its capabilities and expand its technological reach within the cardiovascular sector. These initiatives have not only provided Abbott with enhanced expertise but have also produced synergies that bolster its market presence. The combination of a diverse product line, strong R&D focus, and strategic partnerships contributes to Abbott Laboratories' competitive strengths in the US Artificial Heart Market.
The US Artificial Heart Market has seen significant developments recently. In October 2023, Medtronic announced advancements in their cardiac devices, promising improved patient outcomes and extending the lifespan of artificial hearts. Abbott Laboratories continues to focus on innovation, recently unveiling new clinical data supporting their heart pump systems. Boston Scientific is also actively participating in clinical trials aimed at enhancing device efficiency and patient care.
On the mergers and acquisitions front, Terumo Cardiovascular Systems officially acquired certain assets related to heart pump technology from a smaller firm in September 2023, enhancing their portfolio in this sector. The market valuation for companies like LifeTech Scientific and St. Jude Medical has shown growth due to rising demand for heart assist devices, bolstered by an increasing number of heart failure cases in the US. Moreover, the collaboration between Cleveland Clinic and SynCardia Systems in November 2022 has been pivotal in integrating advanced technology into cardiac care. These trends indicate a robust market environment driven by medical breakthroughs and strategic partnerships. Major developments in the last few years indicate a focus on patient-centered innovations and technological advancements in artificial hearts, critically impacting therapy options available in the US.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 1.05(USD Billion) |
| MARKET SIZE 2024 | 1.25(USD Billion) |
| MARKET SIZE 2035 | 6.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 15.327% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Medtronic, Abbott Laboratories, Boston Scientific, Terumo Cardiovascular Systems, LifeTech Scientific, Evaheart, St. Jude Medical, CardiacAssist, Carmat, Corphenex, CircuLite, Cleveland Clinic, SynCardia Systems, MediCure, AorTech International |
| SEGMENTS COVERED | Type, End User |
| KEY MARKET OPPORTUNITIES | Rising prevalence of heart diseases, Technological advancements in devices, Increasing aging population, Growing demand for transplant alternatives, Expanding reimbursement policies for artificial hearts |
| KEY MARKET DYNAMICS | Aging population, Rising cardiovascular diseases, Technological advancements, Increasing healthcare expenditure, Regulatory approvals and innovations |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Artificial Heart Market is expected to be valued at 1.25 billion USD in 2024.
By 2035, the US Artificial Heart Market is projected to reach 6.0 billion USD.
The expected CAGR for the US Artificial Heart Market from 2025 to 2035 is 15.327 percent.
By 2035, Ventricular Assist Devices (VADs) are projected to be the largest segment, valued at 2.25 billion USD.
Key players in the US Artificial Heart Market include Medtronic, Abbott Laboratories, and Boston Scientific among others.
The Mechanical Heart segment is expected to have a market value of 0.3 billion USD in 2024.
Growing prevalence of cardiac diseases and technological advancements are key growth drivers in the market.
The Total Artificial Hearts segment is expected to reach a value of 1.0 billion USD by 2035.
The Heart-Lung Machine segment is projected to be valued at 1.25 billion USD by 2035.
Challenges such as high costs and regulatory hurdles are currently impacting the US Artificial Heart Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
